| Vericel Corporation |
69866200503 |
NexoBrid (anacaulase-bcdb) For topical gel - 4.85 g anacaulase-bcdb in 5 g lyophilized powder. For Topical Use Only. |
Brand |
FDA |
2023-01-16 |
3150.0000 |
None |
1 |
25500 |
None |
None |
2019-05-07 |
17500000.0000 |
None |
The agreement states an upfront payment of $17.5 million, with an additional $7.5 million payment contingent upon U.S. approval and up to $125 million contingent upon meeting certain annual sales milestones. |
None |
None |
| Verrica Pharmaceuticals Inc. |
71349007001 |
YCANTH 0.7% (w/v) |
Brand |
FDA |
2023-08-24 |
685.0000 |
Verrica is targeting health care professionals in the pediatric and dermatology disciplines as well as direct to consumer marketing in the U.S. At Verrica, we are committed to ensuring patients have access to our innovative medicines while preserving our ability to develop future groundbreaking treatments and cures. Verrica considers numerous factors in determining the price of its drugs, including research and development costs; manufacturing supply considerations; patient population; nature of payer for the relevant product; contracts and relationships with customers; and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers. |
None |
70000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Verrica Pharmaceuticals Inc. |
71349007012 |
YCANTH 0.7% (w/v) 12 applicators |
Brand |
FDA |
2023-08-24 |
8220.0000 |
Verrica is targeting health care professionals in the pediatric and dermatology disciplines as well as direct to consumer marketing in the U.S. At Verrica, we are committed to ensuring patients have access to our innovative medicines while preserving our ability to develop future groundbreaking treatments and cures. Verrica considers numerous factors in determining the price of its drugs, including research and development costs; manufacturing supply considerations; patient population; nature of payer for the relevant product; contracts and relationships with customers; and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers. |
None |
70000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Verrica Pharmaceuticals Inc. |
71349007006 |
YCANTH 0.7% (w/v) 6 applicators |
Brand |
FDA |
2023-08-24 |
4110.0000 |
Verrica is targeting health care professionals in the pediatric and dermatology disciplines as well as direct to consumer marketing in the U.S. At Verrica, we are committed to ensuring patients have access to our innovative medicines while preserving our ability to develop future groundbreaking treatments and cures. Verrica considers numerous factors in determining the price of its drugs, including research and development costs; manufacturing supply considerations; patient population; nature of payer for the relevant product; contracts and relationships with customers; and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers. |
None |
70000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Vertex Pharmaceuticals Incorporated |
51167029009 |
CASGEVY (exagamglogene autotemcel), suspension for intravenous infusion |
Brand |
FDA |
2023-12-08 |
2200000.0000 |
Marketing Plan Description
Vertex’s commercial field team in the United States is composed of a small number of individuals, and we focus our United States marketing activities for CASGEVY towards a limited number of physicians and health care professionals who are located at Authorized Treatment Centers (ATCs) in the United States.
The objective of these activities is to raise awareness and understanding about the approved indication, dosing, efficacy and safety data that are consistent with CASGEVY’s FDA approved label.
Specific activities related to physicians and health care professionals include print distribution by the commercial field team to ATCs, digital advertising (e.g., CASGEVY’s product website), and other educational programs.
Specific activities related to people living with sickle cell disease (SCD) and their caregivers include print distribution of patient materials to ATCs care centers and digital advertising (e.g., CASGEVY’s product website and social media pages). Vertex does not engage in traditional direct-to-consumer advertising (e.g., television or mass media). While not part of Vertex’s marketing plan, the company also operates a patient support program, known as Vertex Connects™, that provides educational resources, communications, and support to eligible patients who have been prescribed CASGEVY.
Pricing Plan Description
When determining the price of CASGEVY, we applied a value-based approach that recognizes the holistic value of a one-time therapy:
• Lifetime clinical benefit of CASGEVY as a one-time treatment for patients with SCD facing significant early mortality
• Enables access for all eligible patients regardless of payer type without excessive hurdles to therapy
• Reduced economic impact of lifelong health care expenses and long-term value delivered across healthcare systems and society
• Investment required for ongoing discovery and development of new medicines
The list price of CASGEVY reflects the transformative clinical and economic value that a one-time treatment that eliminates severe vaso-occlusive crises (VOCs) brings to patients and their families, as well as the resulting long-term value delivered across the healthcare ecosystem and society.
• In clinical trials, 93.5% of patients with SCD achieved the primary efficacy endpoint of freedom from VOCs for at least 12 consecutive months.
• List price is within the range of traditional cost-effectiveness thresholds based on external economic modeling. |
None |
16000 |
None |
1 |
None |
None |
None |
None |
There are approximately 120,000 prevalent cases of Sickle Cell Disease (SCD) in the US. Among prevalent cases of SCD, approximately 16,000 have severe disease defined by recurrent vaso-occlusive crises, meet key age criteria, and would be considered for gene therapy.
The acquisition fields are left blank because the product was developed by Vertex in collaboration with CRISPR and not acquired from a third party. |
None |